Pharmazz Inc

11/15/2024

We are thrilled to share the results of our Phase III clinical trial carried out in India in peer reviewed manuscript titled " Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double‑Blind, Placebo‑Controlled, Multicentre, Phase III Clinical Trial" has been published in "Drugs"

In this research the authors explored the efficacy and safety of sovateltide in adult participants with acute cerebral ischemic stroke.This was a randomised, double-blind, placebo-controlled, multicentre, Phase III clinical trial of sovateltide in participants with cerebral ischemic stroke receiving standard of care (SOC) in India. Patients aged 18–78 years presenting up to 24 h after the onset of symptoms with radiologic confirmation of ischemic stroke and a National Institutes of Health Stroke Scale score (NIHSS) of ≥ 6 were enrolled.

The paper concluded that the sovateltide group had a greater number of cerebral ischemic stroke patients with lower mRS and NIHSS scores at 90 days post-treatment than the control group. This trial supported the regulatory approval of sovateltide in India, but a multinational RESPECT-ETB trial will be conducted for US approval.

You can read the full paper here: https://rdcu.be/d0gzO

09/14/2023

Sovateltide is a first of its kind drug to treat acute cerebral ischemic stroke that can be administered up to 24 hours after the onset of symptomsIndia is...

09/14/2023

Pharmazz Inc. and Sun Pharma enter into licensing agreement for introducing Tyvalzi™ (Sovateltide) in India.

Sovateltide is a first of its kind drug to treat acute cerebral ischemic stroke that can be administered up to 24 hours after the onset of symptomsIndia is...

08/03/2023

Pharmazz India hosted some of the well known global stalwarts of critical care medicine in India on 1st August,2023. These stalwarts have gathered in India to thoroughly review and discuss the current FDA-approved Phase 3 protocol for Centhaquine in hypovolemic shock along with EMA’s initial scientific advice and to deliberate, modify, and finalize the protocol accordingly to initiate the study in Europe, UK, and US. It was indeed a proud moment for an Indian Bio-Pharmaceutical company to be on board with such stalwarts in Centhaquine Advisory Board i.e Prof. Jean-Louis Vincent, Prof. Ashish K Khanna, Prof. Daniel De Backer ,Prof. Marlies Ostermann along with Dr Anil Gulati.

06/01/2023

Pharmazz, Inc. Announces Marketing Approval of Sovateltide in India for Acute Cerebral Ischemic Stroke Patients
bit.ly/3N3GeSS

The proportion of acute cerebral ischemic stroke patients with the mRS of 0-2 on day 90 post-randomization was statistically significant (p=0.002) ...

04/01/2023

Recently Pharmazz Inc. participated in 42nd ISICEM, Brussels. Sharing the presentations highlighting Centhaquine, a resuscitative agent, at The ISICEM 2023 Brussels.

03/17/2023

Sharing our latest publication in the prestigious journal “Neurochemistry International.”

Oxidative stress has been established as a well-known pathological condition in several neurovascular diseases. It starts with the increased production of highly oxidizing free radicals (e.g., reactive oxygen species and reactive nitrogen species). It becomes too high for the endogenous antioxidant system to neutralize them, which results in a significantly disturbed balance between free radicals and antioxidants levels and causes cellular damage. This review discusses the mechanisms involved in reactive oxygen species generation in the brain, oxidative stress, and pathogenesis of neurological disorders such as stroke and Alzheimer’s disease and the scope of antioxidant therapies for these disorders.

’sdisease

03/08/2023

Pharmazz Family wishes you all a very safe and prosperous Holi..
Happy Holi

03/07/2023

Success is Not Final; Failure is Not Fatal: the Courage to Continue Counts.

Pharmazz recently celebrated US FDA clearance for the Phase III clinical trial of Sovateltide (PMZ-1620) in Acute Cerebral Ischemic Stroke Patients. We hosted one of India's leading musical groups, , in our office with the family members of all Pharmazians who were part of this incredible achievement. This marks Pharmazz's consecutive second US FDA approval for a molecule developed, researched, and studied in India.

02/16/2023

/PRNewswire/ -- Pharmazz, Inc. ("Pharmazz" or the "Company"), a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat...